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Abstract
Background: Mutations in the three-prime repair exonuclease 1 (TREX1) gene 
have been associated with neurological diseases, including Retinal Vasculopathy 
with Cerebral Leukoencephalopathy (RVCL). However, the endogenous expression 
of TREX1 in human brain has not been studied. Methods: We produced a 
rabbit polyclonal antibody (pAb) to TREX1 to characterize TREX1 by Western 
blotting (WB) of cell lysates from normal controls and subjects carrying an RVCL 
frame-shift mutation. Dual staining was performed to determine cell types ex-
pressing TREX1 in human brain tissue. TREX1 distribution in human brain was 
further evaluated by immunohistochemical analyses of formalin-fixed, paraffin-
embedded samples from normal controls and patients with RVCL and ischemic 
stroke. Results: After validating the specificity of our anti-TREX1 rabbit pAb, 
WB analysis was utilized to detect the endogenous wild-type and frame-shift 
mutant of TREX1 in cell lysates. Dual staining in human brain tissues from 
patients with RVCL and normal controls localized TREX1 to a subset of mi-
croglia and macrophages. Quantification of immunohistochemical staining of the 
cerebral cortex revealed that TREX1+ microglia were primarily in the gray matter 
of normal controls (22.7 ± 5.1% and 5.5 ± 1.9% of Iba1+ microglia in gray and 
white matter, respectively) and commonly in association with the microvasculature. 
In contrast, in subjects with RVCL, the TREX1+ microglia were predominantly 
located in the white matter of normal appearing cerebral cortex (11.8 ± 3.1% 
and 38.9 ± 5.8% of Iba1+ microglia in gray and white matter, respectively). The 
number of TREX1+ microglia was increased in ischemic brain lesions in central 
nervous system of RVCL and stroke patients. Conclusions: TREX1 is expressed 
by a subset of microglia in normal human brain, often in close proximity to the 
microvasculature, and increases in the setting of ischemic lesions. These findings 
suggest a role for TREX1+ microglia in vessel homeostasis and response to  ischemic 
injury.
INTRODUCTION
The autosomal dominant disease Retinal Vasculopathy with 
Cerebral Leukoencephalopathy (RVCL) is characterized by 
a systemic vasculopathy and encompasses the disorders 
reported separately as Cerebroretinal Vasculopathy (CRV), 
Hereditary Vascular Retinopathy (HVR), and Hereditary 
Endotheliopathy with Retinopathy, Nephropathy, and Stroke 
(HERNS). (6,11,24,26,30) RVCL is 100% penetrant by middle-
age when symptoms first develop. Visual defects due to 
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peri-foveal capillary drop-out are typically followed by focal 
and global neurological deficits as well as cognitive decline 
due to white matter lesions in the cerebral hemispheres and 
cerebellum. Neuroimaging from patients with RVCL shows 
punctate, hyperintense lesions in almost all affected patients 
with the majority also developing rim-enhancing mass lesions, 
often associated with edema, as the disease progressed. (26) 
Although the retina and white matter are most prominently 
affected, other organs including the liver and kidney show 
histopathological changes attributable to small vessel disease. 
All patients endure an early death from neurological decline 
due to progressive white matter lesions. The vasculopathy 
is characterized by vascular wall thickening, multilaminated 
basement membranes, and luminal narrowing that can pro-
gress to complete obliteration. The decrease in blood flow 
results in ischemic necrosis and symptomatology, particularly 
in the retina and white matter.
This devastating disease is caused by frame-shift muta-
tions in TREX1, the three prime repair exonuclease 1, 
that result in loss of its carboxy-tail. A truncated protein 
is synthesized and secreted but is lacking the site for 
its attachment to the endoplasmic reticulum (8,33). 
Consequently, the protein becomes mislocated, being 
observed in the cytoplasm and nucleus (24). While 14 
different frame-shift mutations have been identified, the 
most common is the V235fs seen in 13 unrelated kin-
dreds. (26,31) All of the RVCL-associated mutations lead 
to a functional exonuclease distributed diffusely in the 
cytoplasm and nucleus instead of being anchored to the 
endoplasmic reticulum (ER) like the wild-type 
protein.(24)
In a prior report (Supplementary Table 3) (26), we 
described 11 families in carrying five different mutations 
(6/11 V235fs and 2/11 T249fs). By history and genetic 
analyses, these families were not related (26). The results 
are most consistent with the mutations being independ-
ent events with a relative “hot spot” at V235fs site. Since 
publication of this article in 2016, we have now identified 
(as of 04/01/18—M.K. Liszewski and J.P. Atkinson, 
unpublished data) a total of 26 families worldwide in 
which 13 carry the V235fs variant and 13 others have 
fs variants corresponding to amino acid positions from 
236 to 310 in the mature TREX1 protein. Most of the 
families are of European origin including two of 
Ashkenazi-Jewish ethnicity and one family of Chinese 
background in Taiwan.
With respect to the types of mutations in RVCL com-
pared to those in AGS, SLE, and FCL, the RVCL muta-
tions are frame-shift mutations in the tail, while those in 
AGS, SLE, and FCL are mostly missense or nonsense 
and primarily in the enzymatic amino-terminal portion 
of the protein. For readers interested in the various muta-
tions in these other diseases, we refer the reader to two 
recent reviews.(14,26,33)
The physiologic role of TREX1 is incompletely under-
stood but recent studies have supported a role in clearing 
single stranded DNA (ssDNA) derived from endogenous 
retroelements.(29,35) In the absence of functional TREX1, 
ssDNA accumulates and triggers an antiviral state with 
the induction of interferon (IFN) stimulated genes.(5) The 
knock out mouse develops an inflammatory myocarditis 
resulting in death at 2–6 months.(19,29) As such, TREX1 
is thought to play a physiologic role in preventing 
autoimmunity.
These findings are relevant for three other human 
diseases associated with TREX1 mutations, Aicardi–
Gouitères syndrome (AGS), systemic lupus erythematosus 
(SLE), and familial chilblain lupus (FCL).(3,13,14,20) In 
each of these diseases, TREX1 mutations usually decrease 
or abolish exonuclease function. AGS mimics a congenital 
viral infection of the brain and typically manifests as 
a neurodevelopmental disorder in early infancy. As the 
extra-neurological findings in AGS overlap with SLE, 
AGS has been proposed as a genetic model of systemic 
autoimmunity.(14) RVCL though does not clinically or 
pathologically resemble an autoimmune disease but rather 
a premature degeneration of the microvasculature.(26)
Most studies have focused on the exonuclease activity 
of TREX1, for which the carboxy-terminus is not neces-
sary. Recently, it has been shown that the carboxy-
terminus plays a role in suppressing glycan-induced 
inflammation, a function that is lost by the frame-shift 
mutations of RVCL.(8) More recently, mice carrying a 
common RVCL frame-shift mutation have developed 
autoantibodies although this is infrequently observed in 
patients with RVCL.(15,26) However, the mechanism by 
which this mislocalized but enzymatically active exonu-
clease results in a systemic vasculopathy remains 
elusive.
Although TREX1 transcripts have been identified at 
the RNA level in all tissues examined, the endogenous 
expression of the protein has not been studied.(17) Given 
the burden of the neurological disease in RVCL, we 
evaluated the expression of TREX1 in human brain tis-
sue using a rabbit polyclonal antibody (pAb) we produced. 
With the use of immunohistochemical and immunofluo-
rescent staining, we sought to identify the specific cell 
types expressing TREX1 in the brain for insight into 




As insufficient amounts of recombinant wild-type TREX1 
could be recovered by us (unpublished) or others,(10,16,17) 
recombinant V235fs mutant TREX1 was produced in E. 
coli (detailed in the Supplementary Methods).
Antibody purification
The rabbit pAb to TREX1 was purified by precipitation 
with saturated ammonium sulfate for use in WB analyses. 
For immunofluorescence and immunohistochemical stain-
ing, the pAb was further purified by antigen affinity to 
the recombinant E. coli immunogen (V235fs). Details are 
supplied in the Supplementary Methods. The purified Ab 
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preparations were electrophoresed on a Tris-glycine gel 
and stained with Coomassie Blue to assess purity. 
Preincubation of 1 μg/ml Ab with 10 μg/ml recombinant 
E. coli heat shock protein 70 (Hsp70, also known as DnaK; 
ProSpec, Ness Ziona, Israel) was accomplished at 4°C for 
3 h with rotation.
Figure 1. Expression and detection of TREX1 proteins. A. The rabbit 
anti-TREX1 Ab detects the recombinant TREX1 (rV235fs) as well as E. 
coli heat shock protein 70 (Hsp70) in the immunogen on Western blot 
(WB). B. On strips from the same WB, the anti-TREX1 Ab detects a 
band at ~75 kDa in 293T cells (left panel) that is eliminated after pre-
incubation with E. coli Hsp70. The bands at 37 and 32 kDa are 
unchanged. C. A schematic of TREX1 transcript variants with solid red 
bar for coding sequence, open red bar for untranslated regions, and red 
line for intron. Transcript variant 1 retains the intron and encodes a 
longer N-terminus. D. 293T cells transiently transfected with fluorescent 
protein (FP)-tagged wild-type TREX1 (green) for isoforms-A (left panel) 
and B (right panel). Nuclei are counterstained with TO-PRO-3 (blue). 
Scale bar represents 28 μm. E. Representative WB of TREX1 from 293T 
cells transfected with wild-type TREX1 isoforms-B (lane 1) and A (lane 
2) for positive controls and HeLa cells transfected with TREX1 siRNA 1 
(lanes 3 and 7) or 2 (lanes 4 and 8), negative control (NC1, lanes 5 and 9) 
as well as an untreated control (lane 6). Cell lysates were evaluated at 
48 (lanes 3–5) and 72 (lanes 7–9) h after transfection with siRNA. 
Membrane was stripped and reprobed with anti-β-actin Ab as a loading 
control.
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Plasmid construct, cell culture, and transfection
The cDNA for human TREX1 was obtained from OriGene 
Technologies (Rockville, MD) and variants 1 and 4 
(Fig.  1) were cloned into the EcoR1/XbaI sites in the 
pSBC expression vector, with and without an amino-
terminal fluorescent protein (FP) tag. The frame-shift 
mutation was introduced by site-directed mutagenesis 
(QuikChange II Site-Directed Mutagenesis Kit; Agilent, 
Santa Clara, CA).
The TREX1-specific siRNAs were targeted to the following 
sequences, 5′-GGTTGTGACAGCAGATGGTCTTGGCT-3′ 
(siRNA1) and 5′-CAAGGAAGAGCTACAGC CTAGGC 
AG-3′ (siRNA2). A universal negative control (NC1) was 
obtained from Integrated DNA Technologies (Coralville, IA).
Details on transfection of 293T cells with plasmid expres-
sion vectors and HeLa cells with siRNA can be found in 
the Supplementary Methods.
EBV transformed B lymphocytes were generated from 
normal controls and subjects carrying the RVCL 
mutation.(8,24)
PCR and reverse transcription (RT)-PCR
Genomic DNA (gDNA) and RNA were obtained from 
cell lines using the Wizard Genomic DNA purification 
kit (Promega, Madison, WI) and RNeasy Mini Kit (Qiagen, 
Valencia, CA), respectively. RNA was treated with DNase 
I (Invitrogen) to remove DNA contamination. RNA was 
amplified with the Invitrogen SuperScript One-Step RT-PCR 
with Platinum Taq. The gDNA and RNA were amplified 
with Platinum Taq (Invitrogen). The forward and reverse 
primers to detect TREX1 transcript variants 1 and 4 were 
5′-AGCGAGAGCCGCGGGAGAGTG-3′ and 
5′-CACACGCGGTGGTGGAGGAA-3′. The forward and 
reverse primers to amplify TREX1 transcript variant 1 
were 5′-GCCTGCTACGGTGAGTGTGGC-3′ and 
5′-CTGCTGAGCCTGGAGAGGAGC-3′. PCR and 
RT-PCR were performed at 50°C for 30 min to allow 
reverse transcription and followed by 35 cycles at 94°C 
for 15 s, 60°C for 30 s and 72°C for 1 min. The resulting 
products were run on an agarose gel.
Western blotting
Briefly, cell lysates were electrophoresed on 12% Tris-glycine 
gels (Life Technologies, Carlsbad, CA), transferred to a 
nitrocellulose membrane and blocked overnight in 5% non-
fat dry milk in Tris-Buffered Saline and Tween 20 (TBS-T). 
The membrane was incubated with the primary Ab, rabbit 
pAb to TREX1 diluted 1:1000 or mouse monoclonal anti-
β-actin Ab (Sigma Aldrich, St. Louis, MO) diluted 1:5000 
in 5% non-fat dry milk. After washes with TBS-T, the 
membrane was incubated with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary Ab followed by 
additional washes with TBS-T. The Western blots (WB) 
were developed with West Pico SuperSignal (Thermo Fisher 
Scientific, Waltham, MA). The protein bands from WB 
were scanned and quantified using ImageJ (NIH, Bethesda, 
MD).
Immunofluorescence
293T cells were plated in 6-well chamber slides 24 h prior 
to transfection. Cells were transiently transfected 
(TransIT-293 transfection reagent; Mirus, Madison, WI) 
for 24 h before being fixed and permeabilized with acetone. 
Nuclei were counterstained with TO-PRO-3 (Life 
Technologies, Grand Island, NY). Cells were then visual-
ized with a confocal microscope (Zeiss LSM510 META 
Laser Scanning Confocal Microscope; Carl Zeiss 
Microscopy, Jena, Germany).
Frozen sections were fixed with 95% ethanol, 5% glacial 
acetic acid for 30 min and then washed with PBS. Formalin-
fixed, paraffin-embedded (FFPE) sections were hydrated 
sequentially with 5-min washes in xylene x 2, 95% ethanol 
x 2, 70% ethanol, 50% ethanol, and PBS. Antigen retrieval 
was performed in a pressure cooker with 1 mM EDTA pH 
8 buffer for 2 min. After 3 PBS washes, the slides were 
blocked with avidin and biotin solutions (Vector Laboratories, 
Burlingame, CA). Slides were incubated with blocking buffer 
(10% serum diluted in PBS with 1% BSA) for 30 min and 
then with the primary Ab diluted in blocking buffer over-
night at 4°C in a humidified chamber. Human serum was 
included in all blocking buffers to reduce non-specific back-
ground. After PBS washes, the slides were incubated for 1 
h with an appropriate fluorophore-conjugated secondary Ab 
diluted in blocking buffer. The slides were washed with PBS 
and then incubated with TO-PRO-3 diluted 1:200 in PBS 
for 30 min. After PBS washes, coverslips were placed on 
slides using VectaMount Hard Set Fluorescent Mounting 
Media (Vector Laboratories) before visualization by confocal 
microscopy.
The primary Abs used included the rabbit pAb to TREX1 
(1:200, 1 μg/ml), mouse monoclonal anti-CD68 (KP1 at 
1:200; Abcam, Cambridge, MA), mouse monoclonal anti-
MHC II (CR3/43 to HLA-DR-DP-DQ at 1:200; Abcam), 
mouse monoclonal anti-alpha smooth muscle actin (1A4 
at 1:50; Abcam), mouse monoclonal anti-glial fibrillary 
acidic protein (GFAP; 1:200; Sigma) and biotinylated ricinus 
communis agglutinin I (RCA-1; Vector Laboratories). For 
slides stained with biotinylated RCA-1, blocking buffer 
was excluded and the primary Ab was diluted 1:10,000 in 
PBS and the FITC-Avidin secondary was diluted 1:200 in 
PBS. Secondary Abs alone were used as negative 
controls.
Immunohistochemistry
FFPE sections underwent hydration, antigen retrieval, avi-
din–biotin blocking, and incubation with blocking buffer 
and primary and secondary Abs as described above. 
Endogenous peroxidase was quenched with a 3% solution 
of hydrogen peroxidase for 30 min prior to antigen retrieval. 
For slides stained with rabbit pAb to the ionized calcium-
binding adapter molecule 1 (Iba1; Wako, Richmond, VA) 
diluted 1:1000 in blocking buffer, the secondary was a 
biotinylated anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA). The signal on these slides 
was amplified with the Avidin–Biotin–HRP complex (ABC; 
Vector Laboratories) before being developed with the 
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3,3′-diaminobenzidine tetrachloride (DAB) substrate 
(Vector Laboratories) as the chromogen. For slides stained 
with rabbit pAb to TREX1 (diluted 1:200 in blocking 
buffer), the secondary was a peroxidase-conjugated anti-
rabbit IgG (Jackson ImmunoResearch Laboratories). These 
slides were developed with DAB. Coverslips were mounted 
with VectaMount Permanent Mounting Media (Vector 
Laboratories).
Experimental design
Serial sections stained with TREX1 or Iba1 were blinded 
and three sets of 10 consecutive images were obtained 
with a 40X objective for each brain region. Images were 
taken from the cerebral white and gray matter, basal gan-
glia, thalamus, hippocampus, and cerebellar molecular 
layer and white matter. All cell counts were confined to 
undamaged tissue. The total number of cells expressing 
TREX1 and Iba1 were counted for each image. A cell 
was considered to be within a given image only if the 
nucleus was present to prevent counts in two consecutive 
images. The average of all three sets was used for the 
data analysis. For each individual, the percent of TREX1+ 
microglia was calculated relative to the total number of 
Iba1+ cells in that section. The percent of Iba1+ cells in 
the white matter of the cerebral cortex was calculated 
relative to the total number of Iba1+ cells within the white 
and gray matter of that section for each subject. Similarly, 
the percent of TREX1+ cells in the white matter is reported 
relative to the total number of TREX1+ cells on that 
section.
Study subjects
Tissue sections from the frontal lobe, occipital lobe, basal 
ganglia, hippocampus, thalamus, and cerebellum were 
obtained from all subjects except one case of RVCL 
(Table  1). In cases with RVCL or other neurological dis-
eases, additional sections were available. The six normal 
controls were screened for the absence of neuropathology 
on hematoxylin and eosin (H&E) staining.
The five RVCL cases were selected based on the avail-
ability of tissue sections for analysis. All had their diagnoses 
well established at the time of death, including a known 
family history, a frame-shift mutation in TREX1 and clini-
cal manifestations of the characteristic white matter lesions 
and retinal vasculopathy.(26) Except for one case of RVCL 
from the Cleveland Clinic with the T249fs mutation, other 
subjects carried the V235fs mutation. They were from two 
unrelated individuals who underwent complete autopsies 
by the Department of Pathology and Immunology at 
Washington University School of Medicine. Tissue sections 
from all brain regions were available for four of the five 
RVCL cases. In one of the cases only the frontal lobe and 
additional sections from the cerebral cortex were 
available.(12)
At least two cases with radiation necrosis, multiple scle-
rosis, hemorrhagic stroke, and ischemic stroke were selected 
based on a search of the pathology database at the 
Washington University School of Medicine. A 
neuropathologist (GRK) selected the normal controls and 
cases. All tissue sections were de-identified prior to stain-
ing. The clinical demographics and pathological details 
of all subjects are presented in Table  1.
Statistical analysis
In WB analyses, levels of TREX1 were adjusted relative 
to β-actin levels and are reported as mean ± standard 
deviation (SD). For quantification of immunohistochemical 
staining (detailed in Experimental design above), all data 
are presented as mean ± standard error of the mean (SEM). 




To evaluate the specificity of our rabbit pAb to recom-
binant TREX1, we performed WB analyses. Western 
blotting of the recombinant E. coli protein used to 
immunize the rabbits detected a band for the recombi-
nant V235fs TREX1 and a second band at ~70 kDa 
(Fig.  1A). Mass spectroscopy identified this latter band 
as E. coli heat shock protein 70 (Hsp70), which has been 
reported to co-purify with some recombinant proteins.(23) 
Western blots for endogenous TREX1 in 293T cells also 
identified a cross-reacting protein at ~70 kDa which was 
blocked by preincubation of the pAb to TREX1 with 
recombinant E. coli Hsp70 (Fig.  1B). In lysates from 
293T cells transfected with YFP-tagged TREX1 (wild-
type and V235fs), the rabbit anti-TREX1 Ab detects bands 
of the same mol wt as anti-YFP (not shown).
Two major bands at 37 and 32 kDa were detected in 
293T cells (Fig.  1B) along with an unidentified light band 
at 27 kDa, intermittently seen on WBs, which may be a 
fragment of TREX1 as reported previously.(17) The band 
at 32 kDa corresponds to TREX1 transcript variant 4 
(NM_033629.4), encoding isoform-B (NP_338599.1, 314 amino 







Age at death 
(years)
60.3 ± 5.2 
(range 52-66)
56.0 ± 4.2 
(range 50-60)




3 (50%) 2 (40%) 2 (50%)
Brain weight 
(g)
1251 ± 107 1128 ± 181† 1277 ± 93
Post-mortem 
interval (h)
37.2 ± 32.6 6.1 ± 2.5† 20.5 ± 13.8
RVCL, Retinal Vasculopathy with Cerebral Encephalopathy.
*Tissue from all brain sections unavailable for one subject.
†Data available on four of the five RVCL cases.
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acids) of the wild-type protein (Fig.  1C). The band at 37 
kDa likely represents TREX1 transcript variant 1 
(NM_016381.5) encoding isoform-A (NP_057465.1, 369 amino 
acids), which is included in NCBI databases. Isoform-A retains 
the intron encoding a longer amino-terminus but is otherwise 
identical to isoform-B with respect to the amino acid sequence 
and localization (Fig.  1D). Although small amounts of the 
unspliced transcript encoding isoform-A have been found 
in human tissues (18), expression of the protein has not been 
reported in the literature. Both bands were observed however 
in human monocyte-derived macrophages from peripheral 
blood and four other human cell lines tested, namely HeLa, 
THP-1, U937, and Jurkat (not shown).
We next asked if the band at 37 kDa is indeed isoform-
A of TREX1. The 37- and 32-kDa bands are endogenously 
expressed in HeLa cells and align with the recombinant 
wild-type TREX1 isoforms-A and B transiently expressed 
in 293T cells, respectively (Fig.  1E, lanes 1 and 2). The 
plasmid encoding the longer isoform-A also produces 
isoform-B (lane 2, Fig.  1E), likely from use of the down-
stream start site of transcript variant 4.
HeLa cells transfected with TREX1 siRNA (targeting 
sequences shared by both transcript variants) were then 
analyzed for changes in protein expression at 48 and 72 h. 
Although the levels of TREX1 isoform-B (32-kDa band) were 
found to be decreased at both time points, there was only 
a moderate decrease in the 37-kDa band at 72 h (Fig.  1E). 
As the 37-kDa band showed a greater decrease at 72 h, 
that time point was used for subsequent studies. Three inde-
pendent experiments showed that at 72 h, compared to the 
negative control siRNA, the 32-kDa band was substantially 
reduced (18–35% of control), while the 37-kDa band was 
only moderately reduced (53–63% of control) by TREX1-
specific siRNA (Supplementary Fig. 1A).
The presence of messenger RNA (mRNA) from both 
transcript variants was also studied in 293T, HeLa and 
EBV transformed B lymphocytes from normal controls 
and carriers of the RVCL frame-shift mutation 
(Supplementary Fig. 1B). Primers designed to anneal 
outside the retained intron in transcript variant 1 allowed 
differentiation of the two transcripts based on size. From 
RT-PCR of total mRNA from 293T cells, we observed 
two bands corresponding to transcripts 1 and 4 of TREX1. 
On the other hand, HeLa cells and the EBV transformed 
lymphocytes had one major band corresponding to tran-
script 4 and a faint band corresponding to transcript 1. 
The PCR, run in parallel on the mRNA from both cell 
lines, showed no product even though genomic DNA 
was able to amplify a band the same size as transcript 
1. Thus, genomic DNA contamination was not responsible 
for the band attributed to transcript 1. To further verify 
the presence of transcript variant 1 in the cell lines 
examined, primers were designed to specifically amplify 
it. In all the cell lines examined, transcript variant 1 
was detected by RT-PCR of mRNA but not PCR, which 
would amplify genomic DNA (Supplementary Fig. 1C). 
Thus, transcript variant 1 is expressed at the mRNA 
level and these results indicate that our Ab is detecting 
TREX1 isoform-A.
Endogenous expression of TREX1 frame-shift 
mutants associated with RVCL
Using EBV transformed B-lymphocytes from normal controls 
and carriers heterozygous for the V235fs mutant, the endog-
enous expression of TREX1 was evaluated by WB (Fig.  2). 
293T cells transfected with both isoforms of wild-type TREX1 
and the frame-shift mutants were included as positive controls 
(Fig.  2A, lanes 1–2 and 9–10). The proteins from transcript 
variant 4 (corresponding to isoform-B) were detected at their 
expected molecular weight (32 kDa and 25 kDa for wild-
type and V235fs mutant, respectively; lanes 1 and 2). As 
noted above, the wild-type isoform-A was detected at 37 
kDa but the transfected cells also produced similar amounts 
of isoform-B (32 kDa; lane 9). The RVCL mutation in isoform-
A, V290fs, should be detected at ~30 kDa. However, the 
transfected cell lysates produced a smear, probably due to 
degradation, and a 25-kDa band corresponding to the V235fs 
mutant (lane 10).
Endogenous levels of TREX1 were observed in the EBV 
transformed B lymphocytes from normal controls and het-
erozygous carriers of the RVCL mutation (Fig.  2A, lanes 
3–8). For each subject, 1 x 106 cell equivalents were loaded 
to detect the protein (with a 1-min exposure), though trans-
fected protein was detected in ~3 x 105 cell equivalents. In 
contrast, β-actin levels were easily detected (with a 2 s 
exposure) for each subject but not for the transfected cell 
lysates, which indicates that TREX1 is expressed endoge-
nously at low levels. Wild-type TREX1 was observed in all, 
regardless of genotype. However, the amount of wild-type 
isoform-B in carriers of the frame-shift mutation was about 
60% (range 41–82%; 50% expected) of that present in normal 
controls (Fig.  2B). The levels of the 37-kDa band, likely 
representing TREX1 isoform-A, did not show the same vari-
ability with respect to genotype. In addition, the 37-kDa 
band did not have a consistent pattern with respect to the 
32-kDa band; sometimes both were detected in equal amounts 
while at other times one or the other was more highly 
expressed.
As expected, the endogenous V235fs mutant was 
observed only in carriers with the RVCL mutation 
(Fig. 2A, lanes 4, 6, and 8). The expression of the V235fs 
mutant was ~27% (range 13–44%) of wild-type TREX1 
isoform-B in normal controls (Fig.  2B), less than the 
50% expected in heterozygous carriers. The V290fs, which 
was poorly detected even in transfected cell lysates, was 
not detected in any of the carriers. This may be because 
the V290fs is not stable when expressed (similar to the 
transfected protein) or is expressed below the level of 
detection.
Optimization of rabbit pAb to TREX1 for 
staining in human brain tissue
We next investigated the utility of the rabbit pAb for stain-
ing of tissue sections from human brain. Although the serum 
from the final bleed was satisfactorily employed for WB, it 
resulted in a high background when staining tissue. However, 
a two-step process of purifying the IgG fraction from the 
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saturated ammonium sulfate precipitation over an antigen-
affinity column yielded an Ab preparation with minimal 
background on tissue staining. This Ab was used for all 
immunofluorescence and immunohistochemistry studies.
In 293T cells transfected with FP-tagged TREX1, the 
Ab only stained transfected cells but not untransfected 
cells (Fig.  3A). In order to verify that the staining was 
not due to the cross-reacting band observed at ~70 kDa 
on WB, we stained sections with the Ab alone and Ab 
pre-incubated with E. coli Hsp70 (Fig.  3B). Equivalent 
staining was observed for both indicating that the Ab 
preparation used was specific for TREX1. No staining 
Figure 2. Endogenous expression of TREX1 in normal controls and 
heterozygous carriers of the V235fs mutant. A. Representative Western 
blot of transfected TREX1 in 293T cells (lanes 1–2, 9–10) and 
untransfected EBV transformed lymphocytes from normal controls and 
RVCL mutation carriers. The transfected protein is detected for both 
isoforms of wild-type (WT, lanes 1 and 9) and the frame-shift mutant of 
isoform-B (V235fs, lane 2). The frame-shift mutant of isoform-A (V290fs, 
lane 10) is not well seen. Both the wild-type and frame-shift mutant of 
isoform-A also produce the smaller isoform-B (*). Endogenous WT 
TREX1 is detected in all EBV transformed lymphocytes. The 37 kDa 
band represents TREX1 isoform-A (lanes 3–8). The V235fs mutant is 
detected in cell lines derived from heterozygous carriers of the mutation 
(lanes 4, 6, and 8) but not in normal controls (lanes 3, 5, and 7). 
Endogenous expression of the V290fs mutant is not detected. 
Membrane was stripped and reprobed with anti-β-actin as a loading 
control. B. The expression of TREX1 protein was normalized to a β-actin 
loading control. For each group, Control WT, Carrier WT and Carrier 
V235fs, data are shown for the 3 individuals analyzed followed by the 
average for that group. TREX1 levels are given relative to the average of 
WT in the 3 normal controls (Average Control), which was arbitrarily set 
to 1.0. Data are presented as mean ± SD and represent 8 independent 
samples.
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Figure 3. Specificity of rabbit pAb to TREX1. A. Immunofluorescent 
staining of 293T cells transfected with fluorescent protein-tagged wild-type 
TREX1 (FP-TREX, green) using the rabbit pAb to TREX1 (red) shows that 
the signals overlap (yellow). Scale bar represents 28 μm. B. 
Immunohistochemical staining of human brain tissue with rabbit pAb to 
TREX1 alone (left panel) and after pre-incubation of the Ab with E. coli heat 
shock protein 70 (Hsp70, right panel). Scale bar represents 100 μm. C. 
Immunohistochemical staining of human brain tissue with secondary Ab 
alone (left panel) or rabbit pAb to TREX1 (right panel). Scale bar represents 
40 μm.
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Figure 4. TREX1 positive cells are microglia and/or macrophages. A. 
Dual staining of frozen tissue from a case of RVCL with anti-MHC II 
(top panel, green) and anti-CD68 (bottom panel, green), microglial 
markers, and anti-TREX1 (red). Nuclei are counterstained with TO-
PRO-3 (blue). Scale bar represents 28 μm. B. Two examples (upper 
and lower panels) of dual staining of formalin-fixed, paraffin-embedded 
human brain tissue from a normal control with RCA-1 (left panel, 
green), a microglial/macrophage and endothelial cell marker, and anti-
TREX1 (red). Nuclei are counterstained with TO-PRO-3 (blue). Some 
cells stained with RCA-1 but not TREX1 are endothelial cells based on 
their morphology. Scale bars represent 28 μm on top panel and 14 μm 
on bottom panel. 
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was observed in tissue sections stained with secondary 
Ab alone as a negative control (Fig.  3C). These data dem-
onstrate the specificity of the Ab in staining for TREX1.
TREX1 expression in human brain tissue is 
restricted to a subset of microglia and 
macrophages
We next asked which cells express TREX1 in human 
brain. Although we had hypothesized that TREX1 would 
be expressed by endothelial cells given the vasculopathy 
observed in RVCL, immunohistochemical staining dem-
onstrated that the protein was in glial cells. Frozen 
sections from autopsy material obtained from a patient 
with RVCL were used for immunofluorescent dual-stain-
ing with several glial markers. Based on the morphology 
of the TREX1+ cells, astrocytes or microglia were the 
most likely candidates. Dual staining with GFAP, an 
astrocyte marker, demonstrated no overlap with the cells 
stained for TREX1 (Supplementary Fig. 2). CD68 and 
MHC II, markers for microglia and macrophages, co-
localized with all TREX1+ cells (Fig.  4A). In almost all 
cases, the TREX1+ cells were likely to be microglia as 
they had the typical ramified morphology and were found 
within the parenchyma. While all TREX1+ cells were 
identified by these markers, not all microglia and mac-
rophages stained positive for TREX1.
To determine if TREX1+ cells are microglia in brain 
tissue from normal controls, we performed immunofluo-
rescent dual-staining on FFPE autopsy tissue. Although 
CD68 and MHC II did not stain well on FFPE tissue, 
RCA-1 did. RCA-1 is a lectin that serves as a marker 
for microglial/macrophages and endothelial cells, which 
can be differentiated based on morphology. Similar to 
the findings observed in frozen sections, the TREX1+ 
cells were predominantly microglia (Fig.  4B), but not all 
microglia were TREX1+. Some TREX1+ cells around the 
vasculature had a rounded morphology, which may be 
representative of perivascular macrophages (Fig.  4B, bot-
tom panel). Thus, TREX1 is a marker for a subset of 
microglia and perivascular macrophages in human brain 
tissue.
Expression of TREX1 in human brain tissue 
from normal controls
To determine the distribution of TREX1+ cells and the 
proportion of microglia they represent in the normal human 
brain, we performed immunohistochemical staining on 
serial sections using TREX1 and Iba1, a marker for micro-
glia and macrophages. Using the Abs in parallel allowed 
us to control for variability in staining due to fixation 
and the age of the sections as well as control for differ-
ences in cellular density. Absolute cell counts are provided 
in Supplementary Fig. 3.
The expression of TREX1 varied considerably among 
the brain regions examined (Fig. 5A). The percent of 
TREX1 expressing microglia (mean of TREX1+ cell count/
Iba1+ cell count within the specified brain region for all 
individuals in the group) was highest in the basal ganglia 
(49.8 ± 9.9% of microglia) followed by the gray matter of 
the cerebral cortex. Unlike the gray matter, fewer TREX1+ 
microglia were identified in the white matter of the cer-
ebral cortex (22.8 ± 5.1% of microglia in gray matter vs. 
5.5 ± 1.9% of microglia in white matter, p ≤ 0.01). Although 
the microglia were equally distributed in the gray and 
white matter of the cerebral cortex (Iba1 stain, 54.8 ± 
2.4% in white matter), TREX1+ microglia were observed 
less frequently in the white matter (TREX1 stain, 21.6 ± 
5.5% in white matter; Fig.  5B-D). As such, the difference 
in the distribution of TREX1+ cells between the gray and 
white matter is not due to a difference in the distribution 
of microglia overall. In addition, while the Iba1+ cells 
were uniformly spread throughout the parenchyma of the 
gray and white matter, TREX1+ cells were not. The TREX1+ 
microglia in the cerebral cortex were often closely associ-
ated with the microvasculature, particularly in the gray 
matter (Fig. 5F). These TREX1+ microglia were either flush 
against the vessel or had foot processes extending to the 
vessel perimeter. Dual staining with anti-TREX1 and anti-
alpha smooth muscle actin, a marker for vascular smooth 
muscle cells and pericytes, showed no co-localization (not 
shown).
In the hippocampus and the deep gray matter of the 
thalamus and basal ganglia, the TREX1+ cells were scat-
tered throughout the parenchyma (Supplementary Fig. 4). 
No differences were observed in the distribution of TREX1+ 
microglia between the hippocampus, subiculum and para-
hippocampus. In the basal ganglia, the TREX1+ microglia 
were noted in both the white matter tracts (pencil fibers 
of Wilson) as well as the surrounding gray matter. In the 
cerebellum, the TREX1+ cells were present in the molecular 
layer and white matter. TREX1 expressing microglia were 
associated with the dentate nucleus in the cerebellum of 
all normal controls (n=5, dentate nucleus not included on 
section from 1 subject). Except for the cerebral cortical 
gray matter and basal ganglia, the percent of microglia 
expressing TREX1 was less than 15% in the regions 
quantified.
Expression of TREX1 in undamaged brain 
tissue from subjects with RVCL
We next studied the expression of TREX1 in the brain 
from cases of RVCL in histologically normal appearing 
tissue. Although there was variability in the percent of 
TREX1 expressing cells in the brain regions examined, 
which was also noted in normal controls, there were dif-
ferences between the two groups (Fig. 5). The most striking 
distinction was the increased expression of TREX1 in the 
white matter of the cerebral cortex from brain tissue of 
RVCL cases (5.5 ±1.9% of Iba1+ microglia in normal con-
trols vs. 38.9 ± 5.8% in RVCL, p ≤ 0.01; Fig.  5A-E). In 
addition, TREX1 expressing cells in the gray matter of 
RVCL cases were decreased compared to normal controls 
(22.7 ± 5.1% in controls vs. 11.8 ± 3.1% in RVCL, p ≤ 
0.02). Although the proportion of Iba1+ microglia in the 
white matter was similar to that of normal controls (54.8 
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Figure 5. Distribution of TREX1 expressing cells. A. Distribution of 
TREX1+ microglia by brain regions in normal controls and cases of RVCL 
and ischemic stroke. The proportion of TREX1 cells is shown relative to 
the mean number of microglia (Iba1 stained cells) for specific areas of the 
brain in normal controls (blue bars) and cases with RVCL (red bars) or 
ischemic stroke (green bars). Sections quantified in RVCL and ischemic 
stroke were taken from undamaged tissue. The number of tissue 
sections included for each observation is noted above the appropriate 
column. White matter (WM); Gray matter (GM). Data are presented as 
mean ± SEM. B-C. Distribution of TREX1 and Iba1 staining in the cerebral 
cortex of normal controls and cases of RVCL and ischemic stroke. The 
proportion of Iba1 (E) or TREX1 (F) cells located in the white matter for the 
frontal lobe, occipital lobe and the cerebral cortex in normal controls (blue 
bars) and cases with RVCL (red bars) or ischemic stroke (green bars). The 
values represent the mean among each group for cell counts in the white 
matter divided by the total cell counts in the white and gray matter for the 
specified region. Sections quantified in RVCL and ischemic stroke were 
taken from undamaged tissue. The cerebral cortex includes sections 
from the frontal, parietal, temporal and occipital lobes. The number of 
tissue sections included for each observation is noted above each 
column. Data are presented as mean ± SEM. D-E. Immunohistochemical 
staining of a normal control and subject with RVCL with Iba1 (left panels) 
and TREX1 (right panels) in the gray (top panels) and white matter (bottom 
panels). For RVCL, undamaged brain tissue is shown. Staining for Iba1 
and TREX1 is developed with DAB (brown). Nuclei are counterstained 
with hematoxylin (blue). Scale bars represent 100 μm. F. Representative 
immunohistochemical staining of normal control gray matter with TREX1 
microglia (DAB, brown) in association with microvasculature (arrows). 
Nuclei are counterstained with hematoxylin (blue). Scale bar represents 
40 μm.
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± 2.4% in controls vs. 53.6 ± 1.7% in RVCL, p = n.s.; 
Fig.  5B), there was a marked increase in the proportion 
of TREX1+ cells in the white matter (21.6 ± 5.5% in con-
trols vs. 83.5 ± 2.3% in RVCL, p ≤ 0.01; Fig.  5C). Thus, 
compared to normal controls, the TREX1+ cells are 
increased in the white matter and decreased in the gray 
matter of RVCL cases, even though the distribution of 
microglia between the gray and white matter is similar 
in both groups. The increased expression of TREX1 in 
the white matter is also observed in the cerebellum of 
RVCL cases compared with normal controls (Fig.  5A).
Another difference between RVCL and normal control 
brain tissue was the distribution of TREX1+ cells within the 
white matter. In RVCL (within histologically normal white 
matter), there were areas without TREX1+ cells while other 
regions on the same tissue section had clusters of TREX1+ 
cells. This is in contrast to normal controls where the TREX1 
expressing cells were more uniformly distributed.
With the exception of the white matter regions, the 
expression of TREX1 was reduced or similar to that seen 
in normal controls in other brain regions (Fig.  5A, 
Supplementary Fig. 3). Within the thalamus, the TREX1+ 
microglia could be observed scattered in both the gray 
and white matter. Similarly, in the basal ganglia the TREX1+ 
cells were located within the white matter tracts (pencil 
fibers of Wilson) and in the adjacent gray matter. In some 
cases, the pencil fibers of Wilson showed TREX1+ cells 
with a rounded morphology, similar to macrophages, even 
though no lesions were observed in the adjacent tissue 
on the section. TREX1+ cells were rarely found in the 
hippocampus. In the cerebellum, TREX1 was primarily 
noted in the white matter while the molecular layer had 
occasional scattered TREX1+ microglia. The dentate nucleus 
was only included in a tissue section from 1 case with 
RVCL making it difficult to compare to the findings in 
normal controls. Except for the white matter and basal 
ganglia, TREX1+ microglia represent less than ~15% of 
all microglia in other regions, similar to our observations 
in normal controls.
Expression of TREX1 in ischemic lesions
We next evaluated the expression of TREX1 in the white 
matter lesions of RVCL cases. The neuropathological find-
ings observed in RVCL consist of scattered areas of ischemic 
necrosis in the white matter associated with wall thickening 
and stenosis of the small blood vessels. (26,12) Given that 
RVCL results in occlusion or loss of small blood vessels, 
we also compared our findings to cases of ischemic stroke 
as that is also a result of disruption in blood flow. In 
ischemic lesions, there was a distinct pattern in most cases 
(11 sections from five subjects with RVCL and 13 sections 
from four subjects with stroke). In close proximity to large 
necrotic areas, often with calcifications, few TREX1+ cells 
were present. In many cases, only an empty cavity sur-
rounded by a variable necrotic zone remained. Bordering 
the lesions, a subset of the round, foamy cells expressed 
TREX1. Dual staining with RCA-1 and TREX1 demon-
strated co-localization (Supplementary Fig. 5). The cell 
morphology in these cases is similar to that of activated, 
ameboid microglia or infiltrating macrophages, cell types 
that cannot be distinguished in human brain tissue sec-
tions with current markers. Moving away from the lesion, 
the TREX1+ cells gradually change their morphology to 
a more ramified appearing microglia (Fig.  6A, bottom 
panel). In ischemic stroke cases, these TREX1+ cells are 
observed in distinct tracts, usually within the adjoining 
white matter (Fig.  6B). Other lesions had none or faintly 
stained TREX1+ cells (five sections from four subjects with 
RVCL and two sections from one subject with stroke). 
The staining was unchanged after pre-incubation of the 
Ab with Hsp70 (not shown).
To determine if the differences noted between normal 
controls and RVCL were applicable to ischemic injury in 
general or were specific to RVCL, we also quantified the 
expression of TREX1 in sections consisting of undamaged 
brain tissue from cases with ischemic stroke. All of the 
groups studied demonstrated variability between different 
brain regions with respect to the percent of microglia 
expressing TREX1 (Fig. 5A). In general, there was a greater 
proportion of TREX1+ microglia in all brain regions with 
stroke compared to normal controls and most regions 
examined in RVCL cases. This increase is likely in response 
to the ischemic injury, as it was not observed in other 
neuropathologies screened (multiple sclerosis, radiation 
necrosis and brain tumors; not shown). Only in the white 
matter of the cerebral cortex did RVCL cases have the 
highest expression of TREX1 (38.9 ± 5.8% of Iba1+ micro-
glia for RVCL vs. 14.5 ± 3.1% for ischemic stroke, p ≤ 
0.01). Similar to normal controls and RVCL cases, microglia 
were evenly distributed between the white and gray matter 
in ischemic stroke (55.0 ± 1.3% of Iba1+ cells in white 
matter, Fig.  5B). In contrast, the proportion of TREX1+ 
cells in the white matter was increased compared to nor-
mal controls but not as highly as in RVCL (40.4 ± 6.8% 
in ischemic stroke, Fig.  5C).
More TREX1+ microglia were observed in ischemic stroke 
compared with normal controls for all brain regions. In 
the cerebellum, an association of TREX1+ cells with the 
dentate nucleus was observed in all stroke cases (n=4), 
similar to our findings in normal controls. However, despite 
the increased expression of TREX1 in ischemic stroke, 
these cells represent less than 30% of microglia in all 
brain regions examined, with the exception of the basal 
ganglia (77.7 ± 6.8% of TREX1+ microglia).
DISCUSSION
We present here the development and characterization of 
a specific rabbit pAb to TREX1 that detects this intracel-
lular protein by WB and tissue staining. Although endog-
enous TREX1 protein from cell lysates has been observed 
by WB,(8,25) our study is the only one to detect TREX1 
isoform-A (37 kDa) and we confirmed the endogenous 
expression of the frame-shift mutants associated with RVCL. 
We also demonstrate the expression of the protein in human 
brain tissue for the first time. Further, dual staining 
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demonstrated that TREX1 is exclusively expressed by a 
subset of microglia and macrophages at our level of 
detection.
Microglia are the tissue resident macrophages of the 
central nervous system (CNS) where they serve multiple 
functions.(2,21) During development they prune extra syn-
apses and facilitate the establishment of the vascular net-
work in the CNS.(1,28) They also perform active surveillance 
of the surrounding tissue to maintain homeostasis and 
respond rapidly to perceived insults such as injury or 
pathogens. Although microglia have been implicated in a 
number of neurodegenerative diseases including Alzheimer’s 
disease, Parkinson’s disease, ischemic stroke and multiple 
sclerosis, our understanding of their primary role in the 
brain is incomplete. Initially thought to represent a homog-
enous population, recently the existence of microglial 
subsets with specialized functions has been proposed.(7) 
Our results, which show the expression of TREX1 is lim-
ited to a subset of microglia, strongly support this view. 
The variation in expression of TREX1 by brain region 
also suggests a specialized physiologic role.
The association of TREX1+ microglia with the micro-
vasculature, particularly notable in normal control gray 
matter, suggests a role for these cells in the development 
and/or maintenance of vessels within the CNS. While we 
had initially hypothesized that TREX1 would be expressed 
in endothelial cells, as RVCL is a systemic vasculopathy, 
the observation that the protein is most highly expressed 
in microglia suggests an alternative that should be con-
sidered for any work pursued in the future. Furthermore, 
as microglia are limited to the CNS, this may explain, 
in part, the prominent vasculopathy affecting the white 
matter and retina in RVCL. Less damage in other organs 
from this systemic small vessel disease may be attributable 
to differences among tissue resident macrophages, more 
efficient repair processes or greater biological reserve. 
Future studies on tissues of other organs from subjects 
with RVCL are needed to determine where TREX1 is 
expressed and in which cell types.
Our studies on TREX1 expression in human brain tis-
sue also demonstrate significant increases in the undamaged 
cerebral white matter of cases with RVCL compared to 
Figure 6. Immunohistochemical staining in white matter lesions with 
anti-TREX1. A. Staining for Iba1 and TREX1 in white matter lesions 
from cases with RVCL (left) or ischemic stroke (right). Representative 
images from chronic lesions are shown (400x magnification) with 
each successive image taken from two high-powered fields away. 
Staining for Iba1 and TREX1 is developed with DAB (brown). Nuclei 
are counterstained with hematoxylin (blue). Scale bar represents 100 
μm. B. Panoramic view of the morphological changes in TREX1+ cells 
around a chronic lesion in ischemic stroke (right side) and their 
tracking in the adjacent white matter (WM) with relative absence of 
TREX1+ cells in the gray matter (GM). Similar findings are noted in 
RVCL lesions. Scale bar represents 1 mm.
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normal controls and ischemic stroke. The increase of 
TREX1+ microglia in all regions of the brain in ischemic 
stroke compared to normal controls suggests that this is 
a general response to ischemia. As such, the increased 
expression of TREX1 in the undamaged white matter of 
RVCL may be indicative of wide-spread ongoing injury 
that is undetectable histologically. The clusters of TREX1+ 
microglia in the white matter of RVCL may correlate with 
this low-level injury (and possibly exacerbate it). In addi-
tion, the sparing of the gray matter in RVCL may explain 
why TREX1+ microglia are less frequent there in com-
parison to ischemic stroke (where gray matter can be 
affected). However, it does not account for why TREX1+ 
microglia are decreased in the cerebral gray matter of 
RVCL compared to normal controls.
Another possibility is that the expression of TREX1 in 
RVCL cases is not the result of tissue injury but rather 
causes the damage. Regions of the brain that are able to 
limit the expression of the mutant TREX1 are therefore 
spared; though how this is regulated remains unexplained. 
In order to differentiate between mutant TREX1 expres-
sion causing the white matter damage in RVCL or being 
increased as result of injury, an animal model that develops 
the clinical manifestations would be valuable.
A role for TREX1 in ischemia is further supported by 
our findings in the lesions of RVCL and ischemic stroke. 
In most lesions, increased expression of TREX1 was 
observed in ameboid microglia and/or infiltrating mac-
rophages. This increase of TREX1+ microglia may be due 
to migration toward the infarct to assist in clearance. 
These findings are consistent with the known response of 
microglial to injury wherein microglia transition to an 
ameboid morphology and migrate toward sites of sterile 
injury.(9,27) We hypothesize that TREX1 assists in phago-
cytosis and clearance of necrotic debris in both macrophages 
and microglia. Although TREX1 degrades cytosolic DNA 
in the cytoplasm, it has not been detected in lysosomal 
compartments.(34) However, it is possible that, in the set-
ting of large necrotic lesions, TREX1 becomes involved 
in degrading DNA waste and that defects in clearance of 
nucleic acids may exacerbate ischemic injury.
Alternatively, TREX1 may serve another function unre-
lated to its exonuclease activity, such as limiting the inflam-
matory activation of phagocytes.(22,25) It is possible that 
RVCL mutants impair this function, which may worsen 
an ischemic insult.
One limitation of our study is that the samples from 
patients with RVCL were predominantly from those car-
rying the V235fs as that is the mutation found in the 
families cared for at our institution. However, this muta-
tion is the one most commonly found across the globe 
in unrelated individuals, being present in approximately 
50% of the families described to date [26 and M.K. Liszewski 
and J. P. Atkinson, unpublished]. Thus, it is possible that 
the individual mutations may demonstrate differences in 
the expression of TREX1. However, that is unlikely as 
the clinical manifestations of RVCL are similar across the 
various mutations discovered to date (4,32) and the one 
case carrying the T249fs mutation demonstrated findings 
that were consistent with what was observed with the 
V235fs mutation. Additional studies including brain tissue 
from subjects with the other RVCL-associated mutations 
will be needed to determine if there is any variability. 
Another limitation of our study is that we are only able 
to observe TREX1 if it was expressed at levels detectable 
by tissue staining. In Western blots we have been able to 
detect endogenous TREX1, albeit in large samples, in vari-
ous different cell types. As such, it is probable that TREX1 
is expressed in additional cell types. Regardless, the detec-
tion of TREX1 in only a subset of microglia and perivas-
cular macrophages suggests that these cell types are of 
particular relevance in future studies of RVCL. Additional 
studies are also needed to determine if the expression of 
TREX1 in the microglia plays a role in other diseases 
associated with mutations in TREX1, such as AGS, SLE 
and FCL, or if there are differences in the expression of 
TREX1 by organs and/or cell types.
In summary, we generated a highly specific rabbit pAb 
that is able to detect endogenous levels of human TREX1 
by WB and tissue staining. With this Ab we localized 
TREX1 to a subset of microglia in human brain tissue. 
Our staining demonstrates an association between these 
TREX1+ microglia and the microvasculature in normal, 
undamaged tissue. The function of these cells still needs 
to be determined but it is possible that the TREX1+ micro-
glia are a specialized subset involved in vessel homeostasis 
and/or the response to ischemic injury. The increase in 
TREX1 expression in ischemic stroke strongly indicates 
that it plays a role in the handling of necrotic debris. 
Further studies clarifying this exact relationship of TREX1+ 
microglia with the microvasculature and with ischemic 
lesions should provide insight into how a functional but 
mislocalized exonuclease results in the clinical manifesta-
tions of RVCL.(8,26)
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SUPPORTING INFORMATION
Additional supporting information may be found online 
in the Supporting Information section at the end of the 
article.
Figure S1. Expression of TREX1 protein isoforms and tran-
script variants. A. The level of TREX1 protein was normal-
ized to a β-actin loading control. The level of TREX1 was 
expressed relative to the negative control (NC1) which was 
arbitrarily set to 1.0. Light and dark blue bars represent 
the 37- and 32-kDa bands, respectively. Data, presented 
as mean ± SD, are the result of three independent sam-
ples. B. Reverse-transcriptase PCR (RT-PCR) of DNase I 
treated RNA from 293T (lane 1), HeLa (lane 2) cells, and 
EBV-transformed lymphocytes from carriers of the V235fs 
mutation (lanes 3 and 5) and controls (lanes 4 and 6). PCR 
of DNase I treated RNA serves as negative controls for the 
RT-PCR (lanes 7–12). PCR of genomic DNA (gDNA) from 
293T (lane 13) and HeLa (lane 14) serve as positive controls 
for the PCR reaction. Transcript variants 1 and 4 produce 
~600 and 270 base pair products, respectively, with prim-
ers that align to regions shared between both transcripts 
and surrounding the retained intron in transcript variant 
1. C. Same as B with primers designed to detect transcript 
variant 1 only as a ~300 base pair product.
Figure S2. TREX1 expressing cells are not astrocytes. Dual 
staining of formalin-fixed, paraffin-embedded human brain 
tissue from a case of RVCL with anti-glial fibrillary acidic 
protein (GFAP, green), a marker for astrocytes, and anti-
TREX1 (red). Scale bar represents 21 μm.
Figure S3. Absolute cell counts for Iba1 and TREX1 by brain 
region in normal controls and cases of RVCL and ischemic 
stroke. The cell counts for Iba1 (A) and TREX1 (B) for spe-
cific areas of the brain in normal controls (blue bars), cases 
with RVCL (red bars) and cases with ischemic stroke (green 
bars). Sections quantified in RVCL and ischemic stroke were 
taken from undamaged tissue. The number of tissue sections 
included for each observation is noted above each column. 
White matter (WM); Gray matter (GM). Data are presented 
as mean ± SEM.
Figure S4. Representative immunohistochemical staining for 
TREX1 (brown) in normal controls (left panel) and undam-
aged tissue in RVCL cases (right panel) in specified brain 
regions. Nuclei are counterstained with hematoxylin (blue). 
Scale bar represents 100 μm.
Figure S5. TREX1 cells are ameboid microglia or infiltrating 
peripheral macrophages along the edges of ischemic lesions. 
Dual staining of formalin-fixed, paraffin-embedded human 
brain tissue from a case of ischemic stroke with RCA-1 (left 
panel, green), a microglial/macrophage and endothelial cell 
marker, and anti-TREX1 (red). Nuclei are counterstained 
with TO-PRO-3 (blue). Scale bar represents 28 μm.
Table S1. Summary of the tissue sections analyzed. 
